Galera Therapeutics, Inc. (GRTX)
USD 0.02
(8.11%)
USD 0.02
(8.11%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -259 Thousand USD | -127.19% |
| 2022 | -114 Thousand USD | 85.35% |
| 2021 | -778 Thousand USD | -111.41% |
| 2020 | -368 Thousand USD | -37.83% |
| 2019 | -267 Thousand USD | -110.24% |
| 2018 | -127 Thousand USD | -51.19% |
| 2017 | -84 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | - USD | 100.0% |
| 2024 Q1 | -9000.00 USD | 92.91% |
| 2023 Q3 | -12 Thousand USD | 0.0% |
| 2023 FY | -259 Thousand USD | -127.19% |
| 2023 Q4 | -127 Thousand USD | -958.33% |
| 2023 Q2 | -12 Thousand USD | 40.0% |
| 2023 Q1 | -20 Thousand USD | 23.08% |
| 2022 Q4 | -26 Thousand USD | 3.7% |
| 2022 Q2 | -30 Thousand USD | 3.23% |
| 2022 Q1 | -31 Thousand USD | 93.32% |
| 2022 FY | -114 Thousand USD | 85.35% |
| 2022 Q3 | -27 Thousand USD | 10.0% |
| 2021 Q2 | -102 Thousand USD | 3.77% |
| 2021 FY | -778 Thousand USD | -111.41% |
| 2021 Q3 | -106 Thousand USD | -3.92% |
| 2021 Q4 | -464 Thousand USD | -337.74% |
| 2021 Q1 | -106 Thousand USD | 0.0% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | -368 Thousand USD | -37.83% |
| 2020 Q3 | - USD | 0.0% |
| 2020 Q2 | - USD | 0.0% |
| 2020 Q1 | - USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | -267 Thousand USD | -110.24% |
| 2019 Q4 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | -127 Thousand USD | -51.19% |
| 2018 Q4 | - USD | 0.0% |
| 2017 FY | -84 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| America Great Health | 168.58 Thousand USD | 253.629% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -3.6% |
| Aridis Pharmaceuticals, Inc. | - USD | Infinity% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 52.995% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | -45.506% |
| Better Therapeutics, Inc. | -2.72 Million USD | 90.509% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 81.3% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | 161.271% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 98.87% |
| Eloxx Pharmaceuticals, Inc. | - USD | Infinity% |
| Evelo Biosciences, Inc. | - USD | Infinity% |
| Evolutionary Genomics, Inc. | -1.02 Million USD | 74.645% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 96.348% |
| Innovation1 Biotech Inc. | -52.69 Thousand USD | -391.48% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 90.736% |
| Molecular Templates, Inc. | 50.39 Million USD | 100.514% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -117.109% |
| NexImmune, Inc. | -1.02 Million USD | 74.731% |
| Orgenesis Inc. | -5.72 Million USD | 95.476% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 98.99% |
| Point of Care Nano-Technology, Inc. | -4601.00 USD | -5529.211% |
| PaxMedica, Inc. Common Stock | - USD | Infinity% |
| Scopus BioPharma Inc. | - USD | Infinity% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 100.881% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 46.96% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | -11.638% |
| Trevena, Inc. | 1.45 Million USD | 117.801% |
| Vaxxinity, Inc. | -2.23 Million USD | 88.406% |
| Vaccinex, Inc. | -16 Million USD | 98.382% |
| Vicapsys Life Sciences, Inc. | - USD | Infinity% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 47.358% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | 2330.835% |